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Abstract
Background: The prevalence of diabetes mellitus is higher in individuals with Down syndrome
(DS) than in the general population; it may be due to the high prevalence of obesity presented by
many of them. The aim of this study was to evaluate the insulin resistance (IR) using the HOMA
(Homeostasis Model Assessment) method, in DS adolescents, describing it according to the sex, body
mass index (BMI) and pubertal development.
Methods: 15 adolescents with DS (8 males and 7 females) were studied, aged 10 to 18 years,
without history of disease or use of medication that could change the suggested laboratory
evaluation. On physical examination, the pubertal signs, acanthosis nigricans (AN), weight and height
were evaluated. Fasting plasma glucose and insulin were analysed by the colorimetric method and
RIA-kit LINCO, respectively. IR was calculated using the HOMA method. The patients were
grouped into obese, overweight and normal, according to their BMI percentiles. The EPIINFO 2004
software was used to calculate the BMI, its percentile and Z score.
Results: Five patients were adults (Tanner V or presence of menarche), 9 pubertal (Tanner II – IV)
and 1 prepubertal (Tanner I). No one had AN. Two were obese, 4 overweight and 9 normal.
Considering the total number of patients, HOMA was 1.7 ± 1.0, insulin 9.3 ± 4.8 µU/ml and glucose
74.4 ± 14.8 mg/dl. The HOMA values were 2.0 ± 1.0 in females and 1.5 ± 1.0 in males. Considering
the nutritional classification, the values of HOMA and insulin were: HOMA: 3.3 ± 0.6, 2.0 ± 1.1 and
1.3 ± 0.6, and insulin: 18.15 ± 1.6 µU/ml, 10.3 ± 3.5 µU/ml and 6.8 ± 2.8 µU/ml, in the obese,
overweight and normal groups respectively. Considering puberty, the values of HOMA and insulin
were: HOMA: 2.5 ± 1.3, 1.4 ± 0.6 and 0.8 ± 0.0, and insulin: 13.0 ± 5.8 µU/ml, 7.8 ± 2.9 µU/ml and
4.0 ± 0.0 µU/ml, in the adult, pubertal and prepubertal groups respectively.
Conclusion: The obese and overweight, female and adult patients showed the highest values of
HOMA and insulin.
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Background
Down syndrome (DS) is a common chromosomal disor-
der, affecting 1 per 700 live births [1]. Life expectancy has
increased in the last decades, due to the improvement of
the scientific knowledge about the syndrome and its
acquired complications, and also, due to the easier access
and the more recent diagnostic and therapeutic means for
the patients, their families and the multiprofessional
health team that accompany them [2,3].
Early hypotonicity and typical dimorphisms are among
the clinical characteristics of the syndrome. There is a
higher incidence of diseases in various organic systems,
including the endocrinologic system, such as diabetes
mellitus among others [4].
Diabetes mellitus has a higher prevalence in DS than in
the general population [4,5]. It can appear as an autoim-
mune disorder (type 1 diabetes mellitus) or as a disorder
in which the insulin resistance is the predominant physi-
opathological factor (type 2 diabetes mellitus) [6-8].
Insulin resistance may present without any clinical mani-
festation, often, many years before the appearance of
frank diabetes mellitus, which would occur when the pan-
creas failed to secrete enough insulin to compensate such
resistance and keep the person euglycemic [6]. Therefore,
it would be interesting to know the level of insulin resist-
ance in this syndrome, since adolescence, as diabetes mel-
litus evolve with several complications which would
further increase the morbidity and mortality of this popu-
lation. This way, preventive measures could be applied,
such as giving the patient adequate dietetic orientations
and leading him to an early consultation with a nutrition
service, stimulating and developing special programs of
physical activity, treating those who have insulin resist-
ance with medications, which may be a therapeutic
option in the future.
The aim of this study was to estimate the insulin resistance
(IR) through the HOMA (Homeostasis Model Assessment)
method, in adolescents with DS, and to describe it accord-
ing to the sex, body mass index (BMI) and presence of
puberty.
Methods
A descriptive cross-sectional study was designed with 15
out patient adolescents (8 males and 7 females) with
Down syndrome, aged 10 to 18 years.
Adolescents with previously known diabetes mellitus or
impaired glucose tolerance (IGT) or impaired fasting glu-
cose (IFG) were excluded from this study. Furthermore,
the studied patients did not have any comorbidity and did
not use any medication that could compromise the sug-
gested laboratory evaluation, such as anti-hyperlipidemia
drugs, topic or systemic glucocorticoids, anti-hypertensive
drugs, sexual steroids and GnRH analogues.
The local Institutional Ethical Committee approved the
study and the informed consent was obtained from all
patients' parents or tutors.
The adolescents were measured and weighed; the stature
was annotated in meters and the weight in kilograms.
They were also submitted to physical examination,
including the evaluation of the presence of acanthosis nig-
ricans and the pubertal developmental degree according to
Tanner's stage [9]. Considering puberty, they were
grouped, as follows:
• Prepubertal – absence of sexual development;
• Pubertal – pubertal development according to Tanner's
stage II to IV;
• Adult – pubertal development according to Tanner's
stage V or menarche in girls.
Blood samples were collected after a 12-hour overnight
fasting period, for the analysis of plasma glucose and insu-
lin. The glucose levels were analysed by the colorimetric
method, considering the normal range from 70 to 100
mg/dl, according to the American Diabetes Association,
2003. Insulin levels were analysed by a radioimmu-
noassay kit (Linco Research Incorporation). This kit is spe-
cific for human insulin and does not cross react with pro-
insulin (<0.2%). The normal fasting range, for adults,
after an 18-hour fasting period, varies from 5 to 15 µU/ml.
The method's sensitivity is <2 µU/ml, specificity is 100%
and the range value within and between assay variations
are 3.1% and 6.0% respectively.
Insulin resistance was calculated according to the HOMA
method, through the formula: {[glucose(mg/dl)/18] X
insulin(µU/mL)}/ 22.5 [10].
The EPIINFO software version 2004, provided the BMI
and its percentile and Z score.
The adolescents were grouped by the nutritional status
according to the National Center for Health Statistics
2000 – Center for Disease Control and Prevention(CDC –
NCHS) as follows [11]:
• Undernourished – BMI percentile below 5;
• Normal -BMI percentiles 5 to 85;
• Overweight -BMI percentiles 85 to 95;BMC Endocrine Disorders 2005, 5:6 http://www.biomedcentral.com/1472-6823/5/6
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• Obese – BMI percentile above 95.
Results
The mean age of the patients was 12.9 ± 2.6 years (varying
from 10 to 18 years); none had acanthosis nigricans. Con-
sidering puberty, 5 were adults,9 pubertal and 1 prepuber-
tal, and regarding the nutritional status, 2 (13.3%) were
obese, 4 (26.7%) overweight and 9 (60%) normal (Table
1). The mean BMI was 20.9 ± 4.3 (from 15.5 to 29.6) and
the mean BMI Z score was +0.55 ± 0.9.
Considering the total number of patients, the mean values
were: HOMA = 1.7 ± 1.0 (from 0.6 to 3.8), insulin = 9.3 ±
4.8 µU/ml (from 4.0 to 19.3 µU/ml) and glucose = 74.4 ±
14.8 mg/dl (from 52 to 98 mg/dl). Considering sex, the
mean values of HOMA were 2.0 ± 1.0 in females and 1.5
± 1.0 in males.
Considering the subgroups, divided by the nutritional sta-
tus, the mean values were: HOMA: 3.3 ± 0.6, 2.0 ± 1.1 and
1.3 ± 0.6, and insulin: 18.15 ± 1.6 µU/ml, 10.3 ± 3.5 µU/
ml and 6.8 ± 2.8 µU/ml, in the obese, overweight and nor-
mal, respectively (Figure 1).
Considering puberty, the mean values were: HOMA: 2.5 ±
1.3, 1.4 ± 0.6 and 0.8 ± 0.0, and insulin: 13.0 ± 5.8 µU/ml,
7.8 ± 2.9 µU/ml and 4.0 ± 0.0 µU/ml, in the adult, puber-
tal and prepubertal groups, respectively (Figure 2).
Discussion
Insulin resistance may be defined as a diminished
response to the biological actions of insulin; it may
involve not only the carbohydrate metabolism, but also
the lipid metabolism [12]. In pharmacological terms, it
represents a state in which normal amounts of insulin
produce a subnormal biological response. It is character-
ized by hyperinsulinemia and can be associated with nor-
moglycemia or hyperglycemia [13].
The hyperinsulinemic euglycemic clamp has been
regarded as the standard method to evaluate insulin resist-
ance. Considering that it is a difficult and relatively inva-
sive technique that requires a specialized team and, in
general, it is not available to the clinical practice [14],
researchers have been studying other more practical meth-
ods that would be able to measure insulin resistance. One
of these studied methods is the HOMA method, a mathe-
matic model based on measurement of fasting plasma
glucose and insulin levels, which is especially useful for
DS patients in whom the use of other methods based on
the results of an oral glucose tolerance test (OGTT), for
example, would be extremely difficult to perform.
Although it is not as sensitive or reproducible a measure
of IR as the clamp technique, it has been validated both in
adults [10,14] and in children and adolescents without
DS [15,16] and, for this reason, it has been extensively
used, not only in epidemiological studies, but also in clin-
ical practice [10].
In Down syndrome there is a high prevalence of over-
weight and obesity [17-19] and one study suggests that
there may be a different distribution of body fat, more
truncal than peripheral, in such children, which may rep-
resent only one more trait of the syndrome or be the result
of the muscle hypotonicity that is well known to be part
of the syndrome's characteristics, and this may reduce the
activity level and energy needs of these patients [17].
Therefore, the higher frequency of type 2 diabetes mellitus
Table 1: Distribution of patients' data.
CA Sex BMI BMIp BMI Z Puberty Glucose (mg/dl) Insulin (µU/ml) HOMA
10y F 15.7 29.01 -0.55 Pubertal 52 4.4 0.6
10y5m M 17.8 64.79 0.38 Pubertal 71 5.4 0.9
10y7m F 20.7 86.11 1.09 Pubertal 74 10.9 2.0
10y9m F 19.9 80.09 0.84 Pubertal 74 13.7 2.5
10y9m M 15.5 20.5 -0.82 Prepubertal 85 4.0 0.8
11y4m F 26.1 96.81 1.85 Adult 60 19.3 2.9
11y11m M 17.2 39.23 -0.27 Pubertal 72 6.0 1.1
12y4m M 19.4 69.16 0.5 Pubertal 98 7.6 1.8
12y4m F 16 15.17 -1.03 Pubertal 81 6.9 1.4
13y1m M 22.6 88.02 1.18 Pubertal 53 7.4 1.0
13y1m M 23.7 91.93 1.4 Pubertal 69 8.0 1.4
15y6m F 19.8 44.94 -0.13 Adult 82 6.3 1.3
16y4m F 26.3 89.93 1.28 Adult 97 15 3.6
16y10m M 23.7 78 0.77 Adult 57 7.4 1.0
18y M 29.6 95.93 1.74 Adult 91 17 3.8
CA = chronological age; M = male; F = female; BMIp = BMI percentile; BMI Z = BMI Z score.BMC Endocrine Disorders 2005, 5:6 http://www.biomedcentral.com/1472-6823/5/6
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Mean values of HOMA and insulin according to the nutritional classification Figure 1
Mean values of HOMA and insulin according to the nutritional classification. The highest values of HOMA and insulin were 
found in the obese, followed by the overweight, and lastly, by the normal-weighed patients.
Mean values of HOMA and insulin according to the pubertal classification Figure 2
Mean values of HOMA and insulin according to the pubertal classification. The highest values of HOMA and insulin were found 
in the adult, followed by the pubertal, and lastly, by the prepubertal patients.
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in DS may be associated not only with the higher propen-
sity for obesity, but also with large abdominal fat stores,
reflecting larger amounts of visceral adiposity, which may
contribute to insulin resistance [20,21] and consequently,
to the development of type 2 diabetes mellitus in a varia-
ble period of time. Such correlation between type 2 diabe-
tes mellitus and the higher proportion of body fat mass,
mainly concentrated in the abdominal region, has also
been demonstrated by some studies involving type 2 dia-
betic, non-obese [21] or obese individuals, without DS
[13].
Android obesity, that is, the obesity in which there is accu-
mulation of fat in the central region of the body, espe-
cially in the abdomen, is more associated with insulin
resistance than the gynecoid obesity [20]. It is also known
that the visceral adipocytes, when compared to the subcu-
taneous, have a higher basal lipolysis, are poorly sensitive
to insulin and that such characteristics are amplified when
they show hypertrophy [22]. Consequently, this increase
in lipolysis offers more free fatty acids to the liver, which
stimulates, this way, the liver production of glucose and
the inhibition of glucose uptake and its oxidation in mus-
cle tissue [23]. In an attempt to keep euglycemia, insulin
secretion increases and the resultant compensatory hyper-
insulinemia, in obese patients, reduces the expression of
the membrane insulin receptor (down regulation), which
generates more resistance to the insulin action [24].
In the present study, the highest values of HOMA were
found in the obese and overweight patients, but we can
not affirm if such patients really have insulin resistance, as
there is no consensus for ideal HOMA values for children
and adolescents and much less for patients with DS. No
references about insulin resistance indexes in DS were
found in literature. Nevertheless, comparing our results to
those showed in some studies involving youth without
DS, such as the study of Yeckel et al [25], we could say that
none of our patients had IR because such authors found
mean values of HOMA of about 7.00 for normal glucose
tolerant children and adolescents without DS, based on
clamp and OGTT studies, while our highest HOMA value
was 3.8. Nevertheless, such study involved exclusively
moderate to severe obese patients whose BMI was much
higher than that of our obese patients (38.1 × 27.8 respec-
tively), fact that may have contributed to the highest val-
ues of HOMA presented by them, confirming the direct
relation between obesity and HOMA values, which is in
accordance with our results. Moreover, our sample
involved just 2 obese patients; most of them had normal
weight. On the other hand, Allard et al showed lower
mean values of HOMA, ranging from 0.83 to 1.62 in a
representative sample of 2244 children and adolescents
without DS [26]. A study performed in Rio de Janeiro, Bra-
zil, with normal-weighed healthy students, also without
DS, suggested a mean value of HOMA of 2.36 for girls and
2.66 for boys, using the same method of insulin dosage as
the one used in our study [27]. Based on such reference
values of Brazilian children and adolescents, we found 4
(26.7%) patients (3 females and 1 male) in our study with
insulin resistance when assessed through the HOMA
method. Among them, 2 had obesity, 1 overweight and
the other, normal weight, that is, 100% (2/2) of the obese,
25% (1/4) of the overweight and 11.1% (1/9) of the nor-
mal weight groups had insulin resistance. Unfortunately,
our small sample did not permit us to confirm these data
with statistical analysis as referred in previous reports that
correlated obesity and insulin resistance, in obese
patients, without DS [28,29].
We also found higher HOMA values in adolescents with
complete pubertal development than in the pubertal
ones, which was similar to literature data; this fact demon-
strates that puberty represents a period marked by higher
levels of insulin resistance not only in healthy adoles-
cents, but also in those with DS [13,30]. Nevertheless,
healthy adolescents have physiological compensatory
mechanisms that avoid the appearance of deleterious
effects in the future that could result from this reduction
in insulin action, whereas in DS, it may be that mecha-
nisms fail in the adolescent years, resulting in higher insu-
lin resistance levels than in the healthy population of the
same age. The detection of higher HOMA values in
females than in males has been previously described in lit-
erature, but only in adults and in clinically healthy
patients [13].
Conclusion
We conclude that the obese and overweight, female and
adult patients showed the highest values of HOMA and
insulin. Nevertheless, additional studies are necessary,
including larger samples and longitudinal follow-up in
order to confirm the high prevalence of insulin resistance
in Down syndrome, especially in the obese patients, and
to verify if the patients with the highest values of HOMA
may develop any glucose metabolism disturbance in the
future.
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